{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:15:47Z","timestamp":1790748947713,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.annder.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T19:34:20Z","timestamp":1413488060000},"page":"698-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Les mastocytoses"],"prefix":"10.1016","volume":"141","author":[{"given":"S.","family":"Barete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2014.08.002_bib0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Pardanani","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.revmed.2008.01.025","article-title":"Actualit\u00e9s sur la compr\u00e9hension et le traitement des mastocytoses syst\u00e9miques","volume":"30","author":"Georgin-Lavialle","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2014.08.002_bib0015","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.annder.2014.08.002_bib0020","article-title":"\u00c9tiologies et orientation diagnostique devant un flush","author":"Lafont","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2014.08.002_bib0025","first-page":"1","article-title":"Mastocytoses","author":"Barete","year":"2013","journal-title":"EMC Dermatologie"},{"key":"10.1016\/j.annder.2014.08.002_bib0030","first-page":"323","article-title":"Rare form of urticaria","volume":"2","author":"Nettleship","year":"1869","journal-title":"Br Med"},{"key":"10.1016\/j.annder.2014.08.002_bib0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.iac.2004.01.002","article-title":"Urticaria pigmentosa","volume":"24","author":"Brockow","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.annder.2014.08.002_bib0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000182260","article-title":"Dermatoscopic findings of cutaneous mastocytosis","volume":"218","author":"Akay","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2014.08.002_bib0045","first-page":"320","article-title":"Pediatric cutaneous mastocytosis: a review of 180 patients","volume":"7","author":"Ben-Amitai","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.annder.2014.08.002_bib0050","series-title":"Urticaire pigmentaire. Mastocytoses. Dermatologie","first-page":"119","author":"Degos","year":"1953"},{"key":"10.1016\/j.annder.2014.08.002_bib0055","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1046\/j.1365-2133.1998.02190.x","article-title":"Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-alpha and efficacy of interferon-alfa","volume":"138","author":"Chosidow","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0060","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1111\/ijd.12286","article-title":"Intertriginous cutaneous mastocytosis in a 16-year-old boy","volume":"53","author":"Sun","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0065","first-page":"561","article-title":"Mastocytose cutan\u00e9e diffuse sans l\u00e9sion permanente","volume":"121","author":"Legrain","year":"1994","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.08.002_bib0070","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/PAS.0b013e31824c0d92","article-title":"Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma","volume":"36","author":"Auquit-Auckbur","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annder.2014.08.002_bib0075","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity \u2013 report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2014.08.002_bib0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.annder.2014.08.002_bib0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology","volume":"48","author":"Brockow","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0090","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2014.08.002_bib0095","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ibd.21218","article-title":"Gastrointestinal involvement and manifestations in systemic mastocytosis","volume":"16","author":"Sokol","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.annder.2014.08.002_bib0100","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2014.08.002_bib0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0115","doi-asserted-by":"crossref","first-page":"e26375","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2014.08.002_bib0120","doi-asserted-by":"crossref","first-page":"e39468","DOI":"10.1371\/journal.pone.0039468","article-title":"Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression","volume":"7","author":"Moura","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2014.08.002_bib0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00015550152572912","article-title":"Clinical scoring of cutaneous mastocytosis","volume":"81","author":"Heide","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annder.2014.08.002_bib0130","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2014.08.002_bib0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.annder.2014.08.002_bib0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-065X.2008.00742.x","article-title":"The tyrosine kinase network regulating mast cell activation","volume":"228","author":"Gilfillan","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.annder.2014.08.002_bib0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-KIT mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.annder.2014.08.002_bib0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000140630","article-title":"KIT and mastocytosis","volume":"119","author":"Lim","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0155","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1371\/journal.pone.0001906","article-title":"Phenotypic and genotypic characteristics of mastocytosis according to the age of onset","volume":"3","author":"Lanternier","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2014.08.002_bib0160","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2013.098442","article-title":"Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy","volume":"99","author":"Bibi","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.annder.2014.08.002_bib0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2014.08.002_bib0175","series-title":"Histopathologie cutan\u00e9e non tumorale","first-page":"407","article-title":"Mastocytoses","author":"Fraitag","year":"2013"},{"key":"10.1016\/j.annder.2014.08.002_bib0180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0151-9638(07)89281-7","article-title":"Mastocytoses cutan\u00e9es","volume":"134","author":"Fraitag-Spinner","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.08.002_bib0185","first-page":"871","article-title":"FIP1L1-PDGFRA and c-KIT D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia","volume":"89","author":"Tefferi","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.annder.2014.08.002_bib0190","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2044.2004.03757.x","article-title":"Mast cell tryptase: a review of its physiology and clinical significance","volume":"59","author":"Payne","year":"2004","journal-title":"Anaesthesia"},{"key":"10.1016\/j.annder.2014.08.002_bib0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.annder.2014.08.002_bib0200","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2014.08.002_bib0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annder.2014.08.002_bib0210","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0215","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0220","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0248-8663(03)00141-3","article-title":"Le traitement des mastocytoses syst\u00e9miques","volume":"24","author":"Marrache","year":"2003","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2014.08.002_bib0225","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/ALN.0000000000000031","article-title":"Perioperative management of patients with mastocytosis","volume":"120","author":"Dewachter","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.annder.2014.08.002_bib0230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2014.08.002_bib0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000245681","article-title":"Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis","volume":"195","author":"Godt","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2014.08.002_bib0240","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/S0190-9622(03)01483-X","article-title":"Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study","volume":"49","author":"Gobello","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0245","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1468-3083.2011.04098.x","article-title":"Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: study of five cases","volume":"26","author":"Brazzelli","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.08.002_bib0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations","volume":"12","author":"Castells","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1525-1470.1990.tb01020.x","article-title":"Photochemotherapy of dominant, diffuse, cutaneous mastocytosis","volume":"7","author":"Smith","year":"1990","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.annder.2014.08.002_bib0260","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0265","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0270","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","article-title":"Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature","volume":"52","author":"Simon","year":"2004","journal-title":"Pathol Biol"},{"key":"10.1016\/j.annder.2014.08.002_bib0275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2014.08.002_bib0280","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood.V104.11.661.661","article-title":"Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients","volume":"104","author":"Lortholary","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0290","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0151-9638(04)93884-7","article-title":"Mastocytose cutan\u00e9e tumorale diffuse\u00a0: efficacit\u00e9 du 2 chlorod\u00e9oxyad\u00e9nosine ou cladribine","volume":"131","author":"Cogrel","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2014.08.002_bib0295","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2014.08.002_bib0300","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0305","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-KIT receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.annder.2014.08.002_bib0310","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0315","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood.V104.11.1516.1516","article-title":"Imatinib mesylate in treatment of systemic mastocytosis, a phase I\/II trial","volume":"104","author":"Droogendijk","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0320","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0325","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2014.08.002_bib0330","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0335","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.annder.2014.08.002_bib0340","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0345","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2014.08.002_bib0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2703.2703","article-title":"A phase II study of nilotinib, a novel inhibitor of c-KIT, PDGFR, and Bcr-Abl, administrated to patients with systemic mastocytosis","volume":"108","author":"Hochhaus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0355","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningfull and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0360","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annder.2014.08.002_bib0365","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2008.07038.x","article-title":"Thalidomide in advanced mastocytosis","volume":"141","author":"Damaj","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annder.2014.08.002_bib0370","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.leukres.2005.06.007","article-title":"Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing","volume":"30","author":"Koon","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.annder.2014.08.002_bib0375","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annder.2014.08.002_bib0380","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annder.2014.08.002_bib0385","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963814005997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963814005997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:02:21Z","timestamp":1758970941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963814005997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0151963814005997"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2014.08.002","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les mastocytoses","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2014.09.026","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2014.09.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}